A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer

To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.

Inclusion Criteria:

• Female patients with confirmed advanced breast cancer.
• Patients with HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline-based chemotherapy regimen.
• Patients with adequate general well-being, kidney and liver function.

Exclusion Criteria:

• Patients that have any condition that could affect patients safety, interfere with trial results, or makes the patient inappropriate for inclusion into study.
• Patients who have had prior chemotherapy for advanced breast cancer.
• Patients of child-bearing potential who are unwilling to use contraception.